<DOC>
	<DOCNO>NCT02164539</DOCNO>
	<brief_summary>The purpose study evaluate dose-response 4 dos umeclidinium bromide combination fluticasone furoate compare fluticasone furoate monotherapy chronic obstructive pulmonary disease participant asthmatic component . The fluticasone furoate/umeclidinium bromide treatment also compare once-daily inhaled corticosteroid/long-acting beta agonist combination fluticasone furoate/vilanterol .</brief_summary>
	<brief_title>Evaluation Umeclidinium Bromide Combination With Fluticasone Furoate COPD Subjects With Asthmatic Component</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Bromides</mesh_term>
	<criteria>18 year age old COPD evidence asthmatic component demonstrate spirometry , reversibility current therapy screening follow : Postbronchodilator morning ( AM ) FEV1 &gt; =50 % &lt; =80 % predict normal value Visit 1 Pre postbronchodilator FEV1/FVC ratio &lt; 0.7 . Demonstrated reversibility &gt; =12 % &gt; =200 mL increase FEV1 follow albuterol Visit 1 . A need regular controller therapy ( i.e. , inhaled corticosteroid alone combination long‐acting beta‐agonist leukotriene modifier , etc . ) minimum 12 week prior Visit 1 . Outpatient subject smoker nonsmoker . History lifethreatening respiratory event within last 5 year . Unresolved respiratory infection Recent Severe COPD Asthma Exacerbation Risk factor pneumonia Hospitalization pneumonia within 3 month Concurrent respiratory disease chronic obstructive pulmonary disease asthma . Other uncontrolled condition disease state , opinion investigator , would put safety subject risk study participation would confound interpretation efficacy result condition/disease exacerbate study . Viral hepatitis HIV Current chronic history liver disease , know hepatic biliary abnormality Drug milk protein allergy Administration prescription overthecounter medication would significantly affect course COPD asthma , interact study drug Subjects lung volume reduction surgery within 12 month prior screen . Use longterm oxygen therapy ( LTOT ) Requirement nebulized therapy Participation acute phase pulmonary rehabilitation program within 4 week Unstable lifethreatening cardiac disease Abnormal clinically significant 12Lead Electrocardiogram ( ECG ) finding Diseases prevent use anticholinergic</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>GSK573719</keyword>
	<keyword>asthma</keyword>
	<keyword>UMEC</keyword>
	<keyword>FF</keyword>
	<keyword>GSK2829332</keyword>
	<keyword>persistent obstruction</keyword>
	<keyword>GW685698</keyword>
	<keyword>Fluticasone Furoate</keyword>
	<keyword>COPD</keyword>
	<keyword>umeclidinium bromide</keyword>
</DOC>